HPV Throat Cancer in Men: Symptoms, Risk, and Vaccine Facts

Published: July 2025 | Last updated: April 2026

Human papillomavirus is the most common sexually transmitted infection in the United States. By age 50, at least four in five women have been infected with HPV at some point, according to the CDC's basic information page on HPV and cancer, and the agency notes that infection is similarly common in men. Most clear it without ever knowing. For a smaller subset of men carrying high-risk strains in oral tissue, the virus can sit silently for years and then trigger cancer at the back of the throat.

The CDC's HPV-attributable cancer surveillance estimates roughly 13,600 male oropharyngeal (throat and tonsil) cancers caused by HPV each year in the United States, compared with about 11,100 HPV-attributable cervical cancers in U.S. women (CDC HPV-associated cancer case counts). Public-health messaging has not caught up. Most men have heard of HPV in the context of girls' vaccines and Pap smears, not their own throat or tonsils. This article walks through what is happening: how oral HPV transmits, which men face higher risk, what symptoms get mistaken for stress or allergies, and what vaccination and testing can realistically do at different ages.

Why HPV throat cancer is now a men's issue

For two decades the dominant public-health story about HPV centered on cervical cancer prevention in women. That framing was clinically correct at the time, since cervical cancer represented the largest single HPV-related disease burden. It also created a side effect: most men, including many clinicians, did not think of HPV as a male health issue at all.

The numbers have shifted. CDC U.S. Cancer Statistics now report roughly 27,000 HPV-associated cancers per year in U.S. women and roughly 23,000 per year in U.S. men, with the agency noting that female incidence exceeds male incidence at every site except the oropharynx. CDC's site-specific surveillance estimates roughly 13,600 male oropharyngeal cases attributable to HPV each year, the single largest HPV cancer category in U.S. men (CDC HPV cases page). Penile cancer accounts for a much smaller share, and anal cancer is rising in specific populations discussed later in this article.

This shift has two practical implications. First, awareness messaging that excludes men is now misaligned with the cancer site that is growing fastest. Second, because there is no routine screening for oropharyngeal HPV the way there is a Pap smear for cervical HPV, the only reliable male protection is upstream: vaccination before exposure, plus prompt symptom evaluation when something does not resolve.

Most cancers found in the back of the throat, including in the base of the tongue and tonsils, are HPV-positive. In the United States, HPV is thought to cause about 70% of oropharyngeal cancers.

How oral HPV transmission happens

HPV is a skin-to-skin virus, not a fluid-borne one. It spreads when infected epithelial tissue contacts uninfected epithelial tissue, including in the mouth and throat. The most established transmission route for oral HPV is oral-genital contact, with the receptive partner picking up virus from a partner's genital infection. Other documented routes include oral-anal contact and, less commonly, deep open-mouth kissing where one partner has an active oral infection.

Condoms reduce HPV transmission because they reduce skin-to-skin contact, but they do not eliminate it. The virus can sit on areas a condom does not cover. Number of lifetime oral-sex partners is the strongest behavioral risk factor in epidemiologic studies, more so than total sexual partners or any single specific behavior.

Once HPV reaches oropharyngeal tissue (the tonsillar pillars, base of tongue, and soft palate), most infections clear within one to two years through normal immune response. A subset persist. In persistent infections involving high-risk strains, viral DNA integrates into host cells, and over many years the resulting cellular changes can become cancer. HPV-related cancers develop over many years or even decades after persistent infection (National Cancer Institute), which is why many men diagnosed in their 40s or 50s have no idea when they were exposed.

The symptoms men miss for months

Oropharyngeal cancer is hard to feel early because the affected area (back of the throat, tonsillar pillars, base of tongue) is poorly innervated for pain in its early stages. Tumors can grow for months before producing the kind of symptom that prompts a clinic visit. The result is that most HPV-positive oropharyngeal cancers are diagnosed at stage III or IV, even though survival in HPV-positive disease is substantially better than in HPV-negative disease at the same stage.

The symptom pattern men commonly miss or mis-attribute:

• Persistent unilateral sore throat. Cold-related pharyngitis is bilateral and resolves within 7 to 10 days. A sore throat on one side that lasts more than two weeks deserves an exam.
• Lump in the neck or under the jaw. Often the first noticed sign is a painless, firm swelling of a cervical lymph node (not the tonsil itself). Reactive lymph nodes from a cold shrink within two weeks. A node that does not shrink, or that grows, is the single most common presenting sign.
• Ear pain on one side without ear infection. Referred pain from the throat travels through shared nerve pathways. Unilateral ear pain in a person without ear-canal discharge or fever is a known oropharyngeal-cancer presentation.
• Difficulty or catching sensation when swallowing. A persistent feeling that food sticks at the back of the throat, especially with weight loss, warrants imaging.
• Hoarseness or voice change lasting more than three weeks. Often dismissed as smoking, allergies, or reflux.

None of these symptoms is specific to cancer, and most ultimately turn out to be benign. The decision rule clinicians use is not whether the symptom looks serious; it is whether it has lasted more than two weeks without explanation. That is the threshold worth using.

Anatomically, the oropharynx sits between the soft palate and the upper edge of the larynx. The areas where HPV-driven tumors most commonly arise are the palatine tonsils (lying between the tonsillar pillars), the base of tongue (the rear third of the tongue, behind what you can see in a mirror), and the posterior pharyngeal wall.

The strains that cause cancer, and the ones that don't

There are more than 200 known HPV genotypes, but only about 14 are classified as high-risk for cancer. HPV-16 is the most common high-risk strain found in oropharyngeal cancer; the CDC's HPV-and-cancer fact sheet states plainly that HPV-16 is the most common HPV type to cause cancer in the United States (CDC HPV-and-cancer basic information). HPV-18 is the second most common cancer-causing strain overall and dominates in cervical cancer cases, but it contributes less to throat cancers.

Low-risk strains, including HPV-6 and HPV-11, cause genital and oral warts. They do not progress to cancer. Visible warts are an annoyance and can be treated, but their presence is not a marker of cancer risk.

The clinical reality men face is that no available at-home or office test distinguishes which strain you might be carrying in oral tissue. Cervical cancer screening uses a high-risk HPV PCR test on cells from a Pap smear, but the equivalent for the oropharynx is not part of routine care. Some research labs are studying oral-rinse HPV PCR as a screening tool, but it is not FDA-approved for clinical use yet. This is why the prevention conversation in men centers on vaccination, not on testing.

The vaccine: who's eligible, who got missed, and why it still matters at 40

Gardasil 9, the current HPV vaccine in the United States, protects against nine strains: HPV-6 and HPV-11 (which cause genital warts) and seven high-risk strains including HPV-16 and HPV-18. The series is two or three doses depending on age at first dose (CDC HPV vaccine information).

Per ACIP and CDC guidance, three age tiers govern eligibility: routine vaccination at ages 11 to 12 (when the immune response is strongest and exposure is rare), catch-up vaccination through age 26 for anyone not vaccinated on schedule, and shared clinical decision-making for ages 27 through 45 between you and your provider weighing your sexual history and likely benefit. Many adults in the 27-45 range have not been exposed to all nine vaccine strains and can still benefit from coverage of the strains they have not yet encountered.

The vaccine was not routinely recommended for U.S. boys until 2011, five years after the original 2006 recommendation for girls. Men born before about 1995 mostly grew up in a system that did not offer them the shot. This is one of the structural reasons HPV-attributable cancers in men in their 40s and 50s right now are so common: that cohort missed the vaccine entirely.

The vaccine does not treat existing infections. If you already have HPV-16 in your throat, the vaccine will not clear it. It will, however, protect against the eight other vaccine strains, several of which are also cancer-associated. The math still favors vaccination at any age within the approved range for most men who were not vaccinated as adolescents, especially those who have had a small number of partners and may not yet have been exposed to all nine strains.

Higher-risk groups: gay and bisexual men, and men living with HIV

HPV-related cancer risk is not evenly distributed across the male population. Men who have sex with men (MSM) have substantially higher rates of anal HPV infection than heterosexual men, and rates of anal cancer in this population have been climbing for two decades. Men living with HIV face a further compounded risk, because HIV-related immune suppression makes it harder for the body to clear HPV infections, and persistent infections are what drive cancer development.

For oropharyngeal cancer specifically, the data picture is more mixed. Some studies find higher rates in MSM; others find roughly comparable rates across men once you control for number of oral-sex partners. What is clear is that prevention guidelines recommend HPV vaccination for MSM through age 26 (and shared decision-making through 45), and that anal cytology screening (analogous to a Pap smear) is recommended in some guidelines for HIV-positive MSM and is being studied for broader populations.

If you are in either of these categories and were not vaccinated as an adolescent, the vaccine conversation with your provider is especially worth having. The strains the vaccine covers are responsible for the majority of HPV-related anal and throat cancers, and the protective benefit against new strains is real even when you have existing infections.

HIV status is also a relevant input here, because untreated HIV elevates HPV cancer risk meaningfully and is itself something you can test for at home and act on quickly.

Rapid HIV Antibody Test for Co-Risk Screening

HIV 1&2 At-Home Rapid Test Kit

$33.99

Fingerstick blood test for HIV antibodies. Men living with untreated HIV have higher rates of persistent HPV infection, which is the upstream driver of HPV-related cancers. Confirming HIV status is a meaningful piece of any HPV-related risk conversation. Lateral-flow test, results at home in about 15 minutes. A reactive at-home result should be confirmed with a lab test.

Test for HIV at Home

What treatment involves, and what survivorship looks like

HPV-positive oropharyngeal cancers carry a substantially better prognosis than HPV-negative ones at the same stage, per the National Cancer Institute's oropharyngeal cancer treatment summary. This survival difference is large enough that oncologists specifically test for HPV status at diagnosis, because it influences both treatment intensity and prognosis conversations. Treatment, though, is intense.

Standard care for locoregional disease combines radiation therapy to the head and neck (typically six to seven weeks of daily sessions) with chemotherapy. For some patients, transoral robotic surgery is an option that can reduce or eliminate the radiation dose required. Side effects of radiation to the neck include severe sore throat during treatment, taste changes, persistent dry mouth (xerostomia, from damage to salivary glands), dental complications, and difficulty swallowing that can range from temporary to permanent. Many patients require feeding-tube support during treatment.

Survivorship issues that are not always discussed in advance: long-term dental decay risk because of reduced saliva, fibrosis of neck tissues that can affect swallowing or neck mobility for years, and emotional adjustment around an HPV-driven diagnosis (which sometimes carries internalized stigma even though the virus is essentially universal). Cancer centers with experienced head-and-neck programs increasingly run survivorship clinics specifically focused on these long-term issues.

Can you transmit HPV without knowing? Yes.

HPV is silent in most carriers. No symptom reliably signals you have it, and no current test screens men for it. So the realistic answer to whether you can give it to a partner without knowing is yes, and most transmission happens this way.

What this means practically:

• Disclosure of an HPV history is not generally required and is not very meaningful, since most adults will encounter the virus at some point. What matters more is whether your current partners are vaccinated.
• If you have visible warts, abstain from skin-to-skin contact at the affected site until they have been treated and cleared.
• If you are diagnosed with an HPV-related cancer, your partner's risk for developing the same cancer is not dramatically elevated above population baseline. Most exposure will already have happened during your shared sexual history, and most partners will have cleared the virus on their own. Studies of long-term partners of HPV-positive throat cancer patients show oral HPV prevalence similar to the general population.
• Vaccination is the single most useful preventive step for unvaccinated partners under 45. Condoms and dental dams help but do not fully prevent transmission.

What to do this week if this article hit a nerve

If reading this triggered worry, the steps that move the needle are short:

• Check vaccine status. Look up your immunization records or call your primary-care office. If you are under 45 and not fully vaccinated with Gardasil 9, ask about catch-up.
• Note any throat or neck symptom that has lasted two weeks. A persistent unilateral sore throat, neck lump, ear pain, or swallowing change deserves an in-person exam (primary-care or ENT). This is not a wait-and-see situation past the two-week mark.
• Run a baseline STI panel if it has been a while. HPV is not on the panel for men because there is no validated male HPV test, but the related infections that often co-travel (HIV, syphilis, herpes, chlamydia, gonorrhea) are. An at-home combo kit is a reasonable starting point if you do not have a clinic relationship; a clinic visit is the right call if you have current symptoms.
• Talk to current partners about vaccination. Especially if they are under 45 and not yet vaccinated. The vaccine protects them, which protects you, which protects future partners.

None of this is the same thing as a screening test for oral HPV, which still does not exist for men. But each step closes a real risk gap that is currently open in most men's healthcare.

8-in-1 Combo Kit for Adjacent STI Screening

Complete 8-in-1 STD At-Home Rapid Test Kit

$392.00

Rapid lateral-flow panel covering the eight STIs most often co-tested when HPV exposure is part of the risk conversation: HIV, syphilis, hepatitis B, hepatitis C, HSV-1, HSV-2, chlamydia, and gonorrhea. Combination of fingerstick blood tests and self-collected swabs. Validated for adult men and women. HPV is not included because there is no validated at-home male HPV test; for oral or throat HPV concerns, an in-person ENT exam is the right step.

Order the 8-in-1 Combo Kit

1. U.S. Centers for Disease Control and Prevention. HPV-associated cancer surveillance with site-specific case counts, including roughly 13,600 male oropharyngeal cancers and roughly 11,100 cervical cancers attributable to HPV per year in the United States.
2. U.S. Centers for Disease Control and Prevention. HPV vaccine information for the public, including ACIP recommended ages: routine at 11 to 12, catch-up through age 26, and shared clinical decision-making for ages 27 through 45.
3. U.S. Centers for Disease Control and Prevention. U.S. Cancer Statistics on HPV-associated cancers, including approximately 27,000 cases per year in U.S. women and 23,000 per year in U.S. men, with female incidence higher than male incidence at every site except the oropharynx.
4. U.S. Centers for Disease Control and Prevention. Basic information about HPV and cancer, including the figure that at least four in five women have been infected with HPV by age 50 and the statement that HPV-16 is the most common HPV type to cause cancer in the United States.
5. National Cancer Institute. HPV and cancer overview: persistent-infection biology, the long timeline from infection to invasive disease, and the high-risk vs low-risk strain distinction.
6. National Cancer Institute. Oropharyngeal cancer treatment (PDQ) patient summary: HPV status, prognosis differences between HPV-positive and HPV-negative disease, and standard-of-care treatment overview.
7. U.K. National Health Service. Human papillomavirus (HPV) overview for general audiences, including transmission routes and the typical absence of symptoms.

Sam Harper

Sam covers at-home sexual-health testing, public-health guidance, and clinical-testing basics for general audiences. Has been writing about consumer health since 2019, with a focus on translating CDC and WHO guidance into plain-English action items. Not a clinician; articles are summaries, not advice.